Literature DB >> 11114078

Innate defences against viraemia.

I P Singh1, S Baron.   

Abstract

Human blood plasma has been reported to possess nonspecific antiviral activity. This activity is due to several preexisting naturally occurring molecules that are either active against individual members or a family of viruses. These molecules, however, have not been adequately studied to reveal their molecular structures and mechanisms of action presumably because of their low and nonspecific antiviral action. Therefore, their possible role against viraemia remains unknown. Recently, two naturally occurring nonspecific broad-spectrum antiviral agents, University of Texas Inhibitor beta (UTIbeta) glycoprotein and high density lipoprotein, have been described in human serum. They are active against DNA and RNA viruses and one of them, UTIbeta, possesses significant antiviral activity of 40 units/mL. Since preexisting antiviral molecules in serum appear to be the only defence mechanisms available at the onset of viral infection they may have protective significance against viraemia. In view of this potential, we have undertaken to review the properties of these innate viral inhibitory molecules. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11114078      PMCID: PMC7159352          DOI: 10.1002/1099-1654(200011/12)10:6<395::aid-rmv298>3.0.co;2-v

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  30 in total

1.  A QUANTITATIVE ASSAY OF THE IN VIVO PROTECTIVE EFFECT OF GAMMA-INHIBITOR AGAINST INHIBITOR-SENSITIVE A2 INFLUENZA VIRUS STRAINS.

Authors:  F LINK; J SZANTO; O KRIZANOVA
Journal:  Acta Virol       Date:  1964-01       Impact factor: 1.162

2.  Protection of mice against Asian influenza-virus infection by a normal horse-serum inhibitor.

Authors:  A COHEN
Journal:  Lancet       Date:  1960-10-08       Impact factor: 79.321

3.  Different sensitivity of hemagglutinating and hemolytic activities of Sendai virus to non-antibody inhibitors.

Authors:  L Sinibaldi; A De Stasio; P Mastromarino; L Seganti; P Valenti; N Orsi
Journal:  Boll Ist Sieroter Milan       Date:  1979-11-30

Review 4.  Serum inhibitors of myxoviruses.

Authors:  O Krizanová; V Rathová
Journal:  Curr Top Microbiol Immunol       Date:  1969       Impact factor: 4.291

5.  Vertebrate brains contain a broadly active antiviral substance.

Authors:  I P Singh; A K Chopra; D H Coppenhaver; E Smith; J Poast; S Baron
Journal:  Antiviral Res       Date:  1995-08       Impact factor: 5.970

6.  Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo.

Authors:  S K Sambhi; M R Kohonen-Corish; I A Ramshaw
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

Review 7.  The role of tumor necrosis factor in viral disease.

Authors:  C W Czarniecki
Journal:  Antiviral Res       Date:  1993-12       Impact factor: 5.970

8.  Comparison of the activities in inhibition of haemagglutination by different togaviruses for human serum lipoproteins and their constituents.

Authors:  K F Shortridge; W K Ho
Journal:  J Gen Virol       Date:  1976-12       Impact factor: 3.891

9.  A host defense role for a natural antiviral substance in the nervous system.

Authors:  S Baron; A K Chopra; D H Coppenhaver; B B Gelman; J Poast; I P Singh
Journal:  J Neuroimmunol       Date:  1998-05-15       Impact factor: 3.478

Review 10.  Recently described innate broad spectrum virus inhibitors.

Authors:  S Baron; D Niesel; I P Singh; L McKerlie; J Poast; A Chopra; G Antonelli; F Dianzani; D H Coppenhaver
Journal:  Microb Pathog       Date:  1989-10       Impact factor: 3.738

View more
  1 in total

1.  NK and NKT cell-independent contribution of interleukin-15 to innate protection against mucosal viral infection.

Authors:  Navkiran Gill; Kenneth L Rosenthal; Ali A Ashkar
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.